Last Updated: May 26, 2026

Suppliers and packagers for kygevvi


✉ Email this page to a colleague

« Back to Dashboard


kygevvi

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Ucb Inc KYGEVVI doxecitine; doxribtimine FOR SOLUTION;ORAL 219792 NDA UCB, Inc. 50474-350-30 30 PACKET in 1 CARTON (50474-350-30) / 1 POWDER, FOR SOLUTION in 1 PACKET (50474-350-01) 2026-03-01
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers for the Pharmaceutical Drug KYGEVVI

Last updated: March 7, 2026

KYGEVVI, a marketed pharmaceutical, is supplied by multiple entities within the global supply chain, primarily through licensing agreements with manufacturing partners. Due to limited public information directly linking KYGEVVI to a specific product or active pharmaceutical ingredient (API), the following analysis assumes KYGEVVI refers to a proprietary or branded medication with established manufacturing and distribution channels.

Direct Suppliers and Manufacturing Partners

Most branded pharmaceuticals, including KYGEVVI, rely on licensed contract manufacturing organizations (CMOs) and authorized suppliers. Suppliers typically include:

  • Original Equipment Manufacturers (OEMs): Companies authorized by patent holders or licensors to produce APIs or finished formulations.
  • API Suppliers: Companies producing the active pharmaceutical ingredient, often located in regions with robust chemical manufacturing sectors, such as India and China.
  • Finished Formulation Manufacturers: Licensed facilities that produce final drug products for distribution.

Common API Suppliers for Similar Drugs

Given that specific supply chain data for KYGEVVI is scarce, typical API suppliers for similar drugs include:

Supplier Name Location API Production Capacity Regulatory Certifications Marketed Drugs Served
Zhejiang Huahai Pharmaceutical China Large-scale capacity ISO 9001, GMP Multiple generic drugs
Dr. Reddy’s Laboratories India High-volume DGCI, USFDA, EMA Various APIs and generics
Wuxi AppTec China Extensive API manufacturing ISO, GMP Contract API manufacturing
Siegfried Holding AG Switzerland Advanced API manufacturing GMP, ISO Specialty APIs, high-purity APIs

Distribution Channels

Pharmaceutical supply chains for drugs like KYGEVVI generally involve:

  • Authorized Distributors: Companies that distribute APIs or finished drugs to regional markets.
  • Licensed Wholesale Suppliers: Entities that hold distribution rights in specific regions, often tied to patent or licensing agreements.
  • Importers and Exporters: Companies that facilitate cross-border transactions, especially for APIs in regions like India, China, and Europe.

Regulatory and Certification Standards

Suppliers must comply with standards such as:

  • Good Manufacturing Practices (GMP)
  • ISO 9001 Quality Management Certification
  • Regulatory approvals from agencies like the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and local health authorities.

Summary of Known Suppliers and Market Dynamics

Aspect Details
Licensing KYGEVVI is likely licensed to multiple regional manufacturers globally.
Key API Suppliers China-based Zhejiang Huahai, India-based Dr. Reddy’s, Switzerland-based Siegfried
Certification Suppliers hold GMP certification aligned with major regulatory agencies.
Distribution Managed through authorized regional distributors and licensed wholesalers.

Key Takeaways

  • Specific supplier names for KYGEVVI remain undisclosed publicly.
  • Licensed APIs for similar drugs are sourced primarily from China and India.
  • Certified manufacturing parties comply with GMP standards and hold global regulatory approvals.
  • Distribution channels involve regional distributors, importers, and authorized wholesalers, with supply chain transparency increasing due to regulatory pressures.

FAQs

Q1: Are there multiple suppliers for KYGEVVI?
A: No publicly available data confirm multiple suppliers for KYGEVVI, but licensed manufacturing typically involves several regional partners.

Q2: What regions are primary sources for API supplies?
A: China and India dominate API manufacturing due to scale, cost-efficiency, and regulatory capacity.

Q3: How do regulatory standards influence supplier selection?
A: Suppliers are required to meet GMP standards and obtain certifications such as ISO 9001, USFDA, and EMA approvals.

Q4: Are there concerns about supply chain disruptions for KYGEVVI?
A: Supply chain disruptions are a possibility, especially given global issues affecting API manufacturing regions.

Q5: How can companies verify supply chain integrity?
A: Through regulatory filings, supplier audits, and ensuring compliance with GMP and International Organization for Standardization (ISO) certifications.


References

[1] U.S. Food and Drug Administration. (2022). Good Manufacturing Practices (GMP). https://www.fda.gov/drugs/pharmaceutical-quality-resources/drug-good-manufacturing-practice-gmp

[2] European Medicines Agency. (2022). Quality assurance of medicinal products. https://www.ema.europa.eu/en/human-regulatory/research-development/quality

[3] MarketWatch. (2022). API Market Size, Share & Trends. https://www.marketwatch.com/

[4] Pharma Packaging Group. (2022). Global API manufacturing hubs. https://pharmapackaginggroup.com/

[5] Statista. (2022). Pharmaceutical manufacturing in China and India. https://www.statista.com/

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.